Drug intelligence / Profile preview

HP-2002

Development stage: Unknown
Lead developer: Parr Biotechnology
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Parenteral

Overview

**HP-2002** is Huapu Biotechnology's CpG-adjuvanted recombinant hepatitis B vaccine candidate for prevention of hepatitis B virus infection. The vaccine uses a Hansenula yeast expression system and a three-in-one liquid antigen-adjuvant formulation. Its recombinant antigen is intended to induce hepatitis B virus-specific adaptive immunity, while the proprietary CpG adjuvant activates Toll-like receptor 9 to enhance B-cell, plasmacytoid dendritic-cell, humoral, and cellular immune responses. Huapu reported that the Chinese National Medical Products Administration approved its IND on November 10, 2025. ([parrbio.com](https://www.parrbio.com/newsinfo/10806296.html))

Targets

TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on HP-2002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HP-2002.

Explore the full profile